JP3080405B2 - アミノスチルバゾール誘導体及び医薬 - Google Patents

アミノスチルバゾール誘導体及び医薬

Info

Publication number
JP3080405B2
JP3080405B2 JP07526235A JP52623595A JP3080405B2 JP 3080405 B2 JP3080405 B2 JP 3080405B2 JP 07526235 A JP07526235 A JP 07526235A JP 52623595 A JP52623595 A JP 52623595A JP 3080405 B2 JP3080405 B2 JP 3080405B2
Authority
JP
Japan
Prior art keywords
amino
phenyl
ethenyl
sulfonyl
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP07526235A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO1995027699A1 (ja
Inventor
弘義 日高
明 松浦
真人 松田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of JPWO1995027699A1 publication Critical patent/JPWO1995027699A1/ja
Application granted granted Critical
Publication of JP3080405B2 publication Critical patent/JP3080405B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
JP07526235A 1994-04-06 1995-04-05 アミノスチルバゾール誘導体及び医薬 Expired - Lifetime JP3080405B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP6-68252 1994-04-06
JP6825294 1994-04-06
PCT/JP1995/000658 WO1995027699A1 (en) 1994-04-06 1995-04-05 Aminostilbazole derivative and medicine

Publications (2)

Publication Number Publication Date
JPWO1995027699A1 JPWO1995027699A1 (ja) 1996-10-29
JP3080405B2 true JP3080405B2 (ja) 2000-08-28

Family

ID=13368389

Family Applications (1)

Application Number Title Priority Date Filing Date
JP07526235A Expired - Lifetime JP3080405B2 (ja) 1994-04-06 1995-04-05 アミノスチルバゾール誘導体及び医薬

Country Status (14)

Country Link
US (1) US5972976A (enExample)
EP (1) EP0754682B9 (enExample)
JP (1) JP3080405B2 (enExample)
KR (1) KR100293867B1 (enExample)
CN (1) CN1053658C (enExample)
AT (1) ATE207057T1 (enExample)
CA (1) CA2187214C (enExample)
DE (1) DE69523298T2 (enExample)
DK (1) DK0754682T3 (enExample)
ES (1) ES2165911T3 (enExample)
PT (1) PT754682E (enExample)
RU (1) RU2138482C1 (enExample)
TW (1) TW308586B (enExample)
WO (1) WO1995027699A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69824895T2 (de) * 1998-04-15 2005-06-30 Hidaka, Hiroyoshi, Nagoya Verfahren zur bestimmung des gens eines zielproteins mit hilfe eines medikamentes
WO1999058142A1 (en) * 1998-05-12 1999-11-18 Chen Wen Y Use of anti-prolactin agents to treat proliferative conditions
WO2000064875A1 (en) * 1999-04-23 2000-11-02 Nippon Shinyaku Co., Ltd. Method for pulvirizing to fine powder
US6521658B1 (en) 1999-05-28 2003-02-18 Abbott Laboratories Cell proliferation inhibitors
MXPA02005866A (es) * 1999-12-14 2002-10-23 Nippon Shinyaku Co Ltd Derivados de heterociclo y drogas.
JP2004359545A (ja) * 2001-03-08 2004-12-24 D Western Therapeutics Institute 抗癌剤耐性克服剤
CN1237969C (zh) 2001-04-10 2006-01-25 日本新药株式会社 慢性关节风湿病的治疗剂
WO2002087577A1 (en) * 2001-04-26 2002-11-07 Nippon Shinyaku Co., Ltd. Medicines
US6951875B2 (en) * 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
FR2838437B1 (fr) * 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines
JP5149482B2 (ja) * 2002-09-06 2013-02-20 株式会社デ・ウエスタン・セラピテクス研究所 悪性腫瘍を処置するための医薬組成物、方法および使用
WO2006078941A2 (en) * 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Novel sirtuin activating compounds and methods of use thereof
WO2007137196A2 (en) * 2006-05-19 2007-11-29 Threshold Pharmaceuticals, Inc. Tubulin binding anti cancer compounds and prodrugs thereof
US20100198262A1 (en) * 2009-01-30 2010-08-05 Mckinley Laurence M Axial offset bone fastener system
BR112015026048A2 (pt) 2013-04-19 2017-07-25 Univ Arkansas análogos de combretastatina
DK3623362T3 (da) 2013-12-13 2023-01-30 Eurochem Agro Gmbh Gødningsmiddelblanding, der indeholder en nitrifikationshæmmer
WO2015153635A1 (en) 2014-03-31 2015-10-08 Board Of Trustees Of The University Of Arkansas Disubstituted triazole analogs
DE102017201608A1 (de) 2017-02-01 2018-08-02 Eurochem Agro Gmbh 3,4-Dimethylpyrazol enthaltende Mischung und ihre Verwendung
CN112110829B (zh) * 2019-06-19 2023-08-01 复旦大学 一种能结合α-突触核蛋白聚集体的小分子化合物、其制备方法及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69129611T2 (de) * 1990-08-20 1998-12-17 Eisai Co., Ltd., Tokio/Tokyo Sulfonamid-Derivate
JP2790926B2 (ja) * 1990-08-20 1998-08-27 エーザイ株式会社 スルホンアミド誘導体
JP2692467B2 (ja) * 1991-12-09 1997-12-17 ダイキン工業株式会社 空調制御装置の電力供給装置
EP0570594B1 (en) * 1991-12-10 1997-07-30 Shionogi & Co., Ltd. Hydroxamic acid derivative based on aromatic sulfonamide

Also Published As

Publication number Publication date
WO1995027699A1 (en) 1995-10-19
MX9604540A (es) 1997-09-30
ATE207057T1 (de) 2001-11-15
EP0754682B1 (en) 2001-10-17
US5972976A (en) 1999-10-26
KR970702253A (ko) 1997-05-13
EP0754682A1 (en) 1997-01-22
KR100293867B1 (ko) 2001-09-17
PT754682E (pt) 2002-03-28
EP0754682A4 (en) 1998-03-04
CN1145066A (zh) 1997-03-12
RU2138482C1 (ru) 1999-09-27
CA2187214A1 (en) 1995-10-19
TW308586B (enExample) 1997-06-21
DE69523298T2 (de) 2002-06-27
DK0754682T3 (da) 2002-02-04
ES2165911T3 (es) 2002-04-01
DE69523298D1 (de) 2001-11-22
CA2187214C (en) 2002-03-12
CN1053658C (zh) 2000-06-21
EP0754682B9 (en) 2003-09-17

Similar Documents

Publication Publication Date Title
JP3080405B2 (ja) アミノスチルバゾール誘導体及び医薬
EP1259487B1 (en) 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
RU2054004C1 (ru) Производные 3(2н)-пиридазинона или их фармацевтически приемлемые соли и фармацевтическая композиция на их основе
JPWO1995027699A1 (ja) アミノスチルバゾール誘導体及び医薬
JPH06107637A (ja) ベンズアニリド誘導体
JPH089596B2 (ja) ジアリールメチルピペリジンまたはピペラジンのピリジンおよびピリジンｎ−オキシド誘導体、並びにそれらの組成物および使用方法
WO1999024432A1 (fr) Derives de purine et medicament les renfermant en tant qu'ingredient actif
EA009441B1 (ru) Пиразолпиридины и способы их получения и применения
KR20010022108A (ko) 인자 ｘａ를 억제하는 헤테로사이클 유도체
HU193258B (en) Process for preparing piperazine derivatives and acid addition salts thereof
EP3615027B1 (en) Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
WO2022012593A1 (zh) 5，6-二氢吡嗪并[2，3-c]异喹啉化合物
JPH02289548A (ja) ピリジン化合物
SK175999A3 (en) Angiogenesis inhibiting 5-substituted-1,2,4-thiadiazolyl derivatives
RU2248969C2 (ru) Азотсодержащие гетероциклические производные, фармацевтическая композиция на их основе и противораковый агент
WO2022171088A1 (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物
WO2022171126A1 (zh) 作为Wee-1抑制剂的稠环化合物
JPH107571A (ja) 肺癌治療におけるナフタレン誘導体の使用
US7087606B2 (en) Water-soluble phenylpyridazine compounds and compositions containing the same
JP2837318B2 (ja) アンジオテンシンｉｉ拮抗性ピリジン誘導体
MXPA96004540A (en) Aminostilbazole derivative and medicine
WO2022228509A1 (zh) 吡咯并嘧啶衍生物及其制备方法和用途
JPS62223150A (ja) １，４−ベンゾキノン誘導体
JP2009503007A (ja) フェニルピリジン誘導体、それらの製造、及び医薬品としての使用
EP0206623B1 (en) Pyridine derivatives

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090623

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090623

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100623

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100623

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110623

Year of fee payment: 11

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120623

Year of fee payment: 12

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130623

Year of fee payment: 13

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term